The Medical Advisor

Medically Reviewed by: Dr Frank Yap, MD | Written by: OneDayMD Editorial Team | Last Updated: August 20, 2026 | Part of OneDayMD's Metabolic–Immune Cancer series Quick Answer Systems-level cancer control treats cancer as whole-body biological dysfunction, not just a genetic mutation problem. It targets four modifiable host systems— metabolism, immune function, mitochondrial health, and the tumor microenvironment —that determine whether targeted therapy, chemotherapy, and immunotherapy actually work and keep working. It is an integrative framework that sits alongside standard oncology, not a replacement for it. Table of Contents What Is Systems-Level Cancer Control? Why Targeted Therapy Alone Is Insufficient The Five Pillars of Systems-Level Cancer Control New 2026 Evidence: Insulin Resistance and 12 Cancer Types Seyfried's Metabolic Theory & the Press–Pulse Strategy Dietary Metabolic Strategies Repurposed Drugs Targeting Metabolic & Immune Pathw...

OneDayMD Evidence Review Updated: August 2026 Article type: Narrative evidence review / systems-oncology framework Evidence status: Research framework; not a validated cancer treatment protocol Abstract Background: Cancer is not solely a genetic disease. Malignant cells can undergo profound changes in glucose metabolism, mitochondrial function, amino-acid utilization, lipid metabolism, redox biology and interactions with the immune microenvironment. These changes can influence tumor growth, treatment response and resistance. This has generated increasing interest in metabolic oncology. Objective: This review updates the OneDayMD seven-layer metabolic cancer framework and evaluates its major components according to the strength of available evidence. The framework integrates metabolic health, nutrition, standard tumor-directed therapy, investigational repurposed drugs, mitochondrial biology, cancer stem-cell biology, immune metabolism and lifestyle medicine. Methods: Evi...

Executive Summary Cancer is no longer best understood purely as a genetic disease. By 2026, a growing body of research supports a more integrated model: cancer as a metabolic, immunologic, and microenvironmental disorder . This report presents a unified framework: Cancer is a dysregulated adaptive system driven by metabolic flexibility, immune evasion, and microenvironmental control. Key insights: Tumors rely on three dominant fuels : glucose, glutamine, and lactate Mitochondrial dysfunction is central to cancer progression and stemness The tumor microenvironment (TME) actively suppresses immune response Metabolic therapies may enhance—not replace—standard treatments Combination strategies outperform single-agent approaches. Introduction: A Broader View of Cancer Biology Traditional oncology often focuses on genetic mutations and targeted therapies. While mutations are critical, emerging research shows that cancer is also a disease of metabolic dysfunction and immu...